476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1
作者
Igor Bondarenko,John A. Glaspy,Adam Brufsky,Oleg Lipatov,EA Perez,StephenY.T. Chan,X.M Zou,S. Phan,Nicholas J. Robert,Véronique Dièras